Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery.
Gürses
N
N
Department of Pediatrics, Ondokuz Mayis University School of Medicine, Samsun, Turkey.
Uysal
S
S
Cetinkaya
F
F
Işlek
I
I
Kalayci
A G
AG
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D011129:Polyradiculoneuropathy / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D012121:Respiration, Artificial
D016756:Immunoglobulins, Intravenous